News & Updates
Showing Oncology articles
Showing
Intensive testosterone-blocking therapy delays prostate-specific antigen progression in BRPC
A 52-week course of intensified androgen-deprivation therapy (ADT) appears to extend prostate-specific antigen progression-free survival (PSA-PFS) in patients with biochemically recurrent prostate cancer (BRPC) compared with ADT alone, without prolonging time to testosterone recovery, according to the phase III open-label PRESTO trial.
Intensive testosterone-blocking therapy delays prostate-specific antigen progression in BRPC
31 Jan 2024
Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening
Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.
Noncontrast-enhanced MRI superior to US but less cost-effective for HCC screening
31 Jan 2024
Self-adjusted nitrous oxide eases pain during transrectal prostate biopsy
Patient use of self-adjusted nitrous oxide (N2O) at levels of 20 percent to 45 percent during transrectal prostate biopsy is safe and well tolerated, according to a study. Delivery of low-dose N2O is associated with reduced pain, but its effect on anxiety does not seem significant.
Self-adjusted nitrous oxide eases pain during transrectal prostate biopsy
30 Jan 2024
TDM offers benefits in thiopurine-treated children with leukaemia, IBD
Therapeutic drug monitoring (TDM) helps identify children treated by thiopurine for acute lymphoblastic leukaemia (ALL) and inflammatory bowel disease (IBD) who have not reached their target levels or are over treated, reports a recent study.
